The inhibition of monoamine oxidase by esomeprazole

Drug Research

Volumn 63, Issue 9, 2013, Pages 462-467

  Petzer, A ^a   Pienaar, A ^a   Petzer, J P ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

competitive; esomeprazole; inhibition; monoamine oxidase; reversible

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ESOMEPRAZOLE; LAZABEMIDE;

ARTICLE; CONTROLLED STUDY; DIALYSIS; DILUTION; DRUG DETERMINATION; ENZYME ACTIVITY; ENZYME INHIBITOR COMPLEX; IC 50;

EID: 84885040174     PISSN: 21949379     EISSN: 21949387     Source Type: Journal    
DOI: 10.1055/s-0033-1345163     Document Type: Article

References (27)

1. Abelö A., Andersson T. B., Antonsson M. et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos: 2000; 28 966 972
2. Tybring G., Böttiger Y., Widén J. et al. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clin Pharmacol Ther: 1997; 62 129 137
3. Andersson T., Röhss K., Bredberg E. et al. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther: 2001; 15 1563 1569
4. Youdim M. B., Bakhle Y. S. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol: 2006; 147 01 S287 S296
5. Youdim M. B., Edmondson D., Tipton K. F. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci: 2006; 7 295 309
6. Yamada M., Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology: 2004; 25 215 221
7. Fernandez H. H., Chen J. J. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy: 2007; 27 174S 185S
8. Finberg J. P., Wang J., Bankiewicz K. et al. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J Neural Transm Suppl: 1998; 52 279 285
9. Da Prada M., Zürcher G., Wüthrich I. et al. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl: 1988; 26 31 56
10. Ramsay R. R., Dunford C., Gillman P. K. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol: 2007; 152 946 951
11. Stanford S. C., Stanford B. J., Gillman P. K. Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium. J Psychopharmacol: 2010; 24 1433 1438
12. Soriato G., Focati M. P., Brescello R. et al. Pharmaceutical preparations of crystalline lazabemide. Patent: 2008; WO 2008010794
13. Petzer A., Harvey B. H., Wegener G. et al., Azure B. a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase. Toxicol Appl Pharmacol: 2012; 258 403 409
14. Novaroli L., Reist M., Favre E. et al. Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening. Bioorg Med Chem: 2005; 13 6212 6217
15. Strydom B., Bergh J. J., Petzer J. P. The inhibition of monoamine oxidase by 8-(2-phenoxyethoxy)caffeine analogues. Arzneimittelforschung: 2012; 62 513 518
16. Harfenist M., Heuser D. J., Joyner C. T. et al. Selective inhibitors of monoamine oxidase. 3. Structure-activity relationship of tricyclics bearing imidazoline, oxadiazole, or tetrazole groups. J Med Chem: 1996; 39 1857 1863
17. Manley-King C. I., Bergh J. J., Petzer J. P. Inhibition of monoamine oxidase by selected C5- and C6-substituted isatin analogues. Bioorg Med Chem: 2011; 19 261 274
18. Dixon M. The determination of enzyme inhibitor constants. Biochem J: 1953; 55 170 171
19. Aubin N., Barneoud P., Carter C. et al. SL25.1131 [3(S),3a(S)-3- methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a] quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile. J Pharmacol Exp Ther: 2004; 310 1171 1182
20. 2A receptor antagonism. J Biol Chem: 2002; 277 36040 36044
21. Binda C., Aldeco M., Geldenhuys W. J. et al. Molecular insights into human monoamine oxidase B inhibition by the glitazone anti-diabetes drugs. ACS Med Chem Lett: 2011; 3 39 42
22. Hughes J. D., Blagg J., Price D. A. et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett: 2008; 18 4872 4875
23. Kalaria R. N., Harik S. I. Blood-brain barrier monoamine oxidase: enzyme characterization in cerebral microvessels and other tissues from six mammalian species, including human. J Neurochem: 1987; 49 856 864
24. Boulton A. A. Phenylethylaminergic modulation of catecholaminergic neurotransmission. Prog Neuropsychopharmacol Biol Psychiatry: 1991; 15 139 156
25. Lasbennes F., Sercombe R., Seylaz J. Monoamine oxidase activity in brain microvessels determined using natural and artificial substrates: relevance to the blood-brain barrier. J Cereb Blood Flow Metab: 1983; 3 521 528
26. Finberg J. P., Lamensdorf I., Armoni T. Modification of dopamine release by selective inhibitors of MAO-B. Neurobiology (Bp): 2000; 8 137 142
27. Provost J. C., Funck-Brentano C., Rovei V. et al. Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects. Clin Pharmacol Ther: 1992; 52 384 393